News for Inhibikase Therapeutics, Inc. (IKT)

Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will determine its future competitiveness. See more.

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. ( IKT) (”œInhibikase” or ”œCompany”), a clinical-stage pharmaceutic

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON, March 27, 2025 (GLOBE

Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

**media[548530]**

--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vi

-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chai

Overview of the Recent Transaction On December 31, 2024, ADAR1 Capital Management, LLC (Trades, Portfolio) made a strategic move by acquiring 6,994,246 shares o

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a significant transaction involving Inhibikase Therapeutics Inc (IKT). The firm added

On December 31, 2024, Fairmount Funds Management LLC (Trades, Portfolio) executed a notable transaction involving Inhibikase Therapeutics Inc (IKT). The firm ad

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

China-based China Liberal Education Holdings Limited (CLEU) is down over 87 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Stocks Analysis by Professor Ari Zoldan covering: General Motors Company, Dell Technologies Inc, Wells Fargo & Company, Wolfspeed Inc. Read Professor Ari Zoldan's latest article on Investing.com

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding. Click here to read my analysis.

D.E.

Wednesday's Insider Activity: Top Buys and Sells in US Stocks

Shares of Tesla, Inc. TSLA rose sharply in today's pre-market trading after the company reported stronger-than-expected earnings for its third quarter. The aut...

On October 21, 2024, Arvind Kush, a Director at Inhibikase Therapeutics Inc (IKT), purchased 145,000 shares of the company, as reported in a recent SEC Filing.

Overview of the Recent Transaction On October 21, 2024, Perceptive Advisors LLC, a prominent investment firm, initiated a new position in Inhibikase Therapeutic